- Home
- PAM vs PCVX Comparison
PAM vs PCVX Comparison
Compare PAM & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAM | PCVX |
|---|---|---|
| Founded | 1945 | 2013 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 6.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PAM | PCVX |
|---|---|---|
| Price | $90.06 | $46.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $92.75 | ★ $101.67 |
| AVG Volume (30 Days) | 225.0K | ★ 1.5M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $1,926,000,000.00 | N/A |
| Revenue This Year | $136,919.08 | N/A |
| Revenue Next Year | $36.38 | N/A |
| P/E Ratio | $15.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $54.95 | $27.66 |
| 52 Week High | $97.55 | $94.60 |
Technical Indicators
Market Signals| Indicator | PAM | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 62.42 | 51.97 |
| Support Level | $89.01 | $43.78 |
| Resistance Level | $91.02 | $48.11 |
| Average True Range (ATR) | 3.52 | 1.99 |
| MACD | -0.46 | -0.49 |
| Stochastic Oscillator | 66.81 | 42.99 |
Price Performance
Historical ComparisonAbout PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.